Comparing Autolus Therapeutics (AUTL) and Mesoblast (MESO)
Autolus Therapeutics (NASDAQ: MESO) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
This table compares Autolus Therapeutics and Mesoblast’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for Autolus Therapeutics and Mesoblast, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Autolus Therapeutics presently has a consensus price target of $37.50, suggesting a potential upside of 25.00%. Mesoblast has a consensus price target of $15.60, suggesting a potential upside of 161.74%. Given Mesoblast’s higher possible upside, analysts clearly believe Mesoblast is more favorable than Autolus Therapeutics.
Valuation & Earnings
This table compares Autolus Therapeutics and Mesoblast’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mesoblast||$17.34 million||32.37||-$35.29 million||($0.63)||-9.46|
Autolus Therapeutics has higher earnings, but lower revenue than Mesoblast.
Institutional and Insider Ownership
21.1% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Mesoblast shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Autolus Therapeutics beats Mesoblast on 5 of the 8 factors compared between the two stocks.
Autolus Therapeutics Company Profile
Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Mesoblast Company Profile
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.